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Abstract. 
There is inadequate understanding of the biology, pathology, transmission, and control of Plasmodium vivax, the 
geographically most widespread cause of human malaria. During the last decades, study of this species was 
neglected, in part due to the erroneous belief that it is intrinsically benign. In addition, many technical challenges in 
culturing the parasite also hampered understanding its fundamental biology and molecular and cellular responses to 
chemotherapeutics. Research on vivax malaria needs to be substantially expanded over the next decade to accelerate 
its elimination and eradication. This article summarizes key knowledge gaps identified by researchers, national 
malaria control programs, and other stakeholders assembled by the World Health Organization to develop strategies 
for controlling and eliminating vivax malaria. The priorities presented in this article emerged in these technical 
discussions, and were adopted by expert consensus of the authors. All involved understood the priority placed upon 
pragmatism in this research agenda, that is, focus upon tools delivering better prevention, diagnosis, treatment, and 
surveillance of P. vivax. 
INTRODUCTION 
Plasmodium vivax is the most geographically widespread malaria parasite species and 
codominates with Plasmodium falciparum as a cause of human malaria. Plasmodium vivax 
infects tens of millions of people each year.
1
 Despite long being regarded as benign, evidence 
now shows that P. vivax is very often associated with severe, life-threatening, and fatal malaria 
in patients from endemic areas as well as in travelers.
2
 
Where control programs have been intensified in coendemic areas, P. vivax tends to be more 
resilient than P. falciparum.
3–5
 This is due to biological features unique to P. vivax enhancing its 
ability to survive in conditions unsuited to P. falciparum and propagate further transmission.
6
 
The conventional methods of control historically aimed solely at P. falciparum may not suffice. 
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Interventions and strategies aimed specifically at P. vivax would greatly accelerate progress 
against it.
7
 
The following specific characteristics set P. vivax apart from P. falciparum with respect to 
control and elimination: 1) the hypnozoite leads to relapses, repeated clinical attacks, and onward 
transmission; 2) gametocytes emerge at an early stage of infection, before onset of illness; 3) 
transmission by a broad range of anopheline vector species residing in diverse habitats and 
myriad distinct behaviors relevant to transmitting the parasite; 4) more rapid development in the 
vector in comparison to P. falciparum at the same temperature dampens the population effects of 
shortening mosquito life span by insecticide-treated net (ITN) or indoor residual spraying (IRS) 
interventions; and 5) shifts in vector species and behaviors in response to use of long-lasting 
insecticidal nets (LLINs) and IRS.
8
 
To date, the only drug approved to eliminate the hypnozoite of P. vivax is primaquine (PQ). 
This drug sometimes causes life-threatening acute hemolytic anemia in patients with a deficiency 
in glucose-6-phosphate dehydrogenase (G6PD). G6PD status is essential to safe treatment with 
PQ, but that diagnosis is rarely available at the health facilities where most malaria patients 
present. As currently recommended by the World Health Organization (WHO),
9
 PQ requires a 
14-day daily treatment course. Counseling strict adherence carries the risk of serious harm in 
G6PD-deficient patients. These factors, along with fear of PQ by providers and patients alike, 
sharply erode the utilization and therefore the effectiveness of PQ in practice. PQ is a 
spectacularly inadequate and ineffective anti-infective drug. Safer and more easily administered 
drugs are needed to improve treatment of patients infected by P. vivax and enable attacking the 
tenacious and harmful hypnozoite reservoir residing in endemic communities virtually 
unmolested by any intervention against it. 
Scientific progress in P. vivax since 1960 has been minimal compared with those in P. 
falciparum because P. vivax was inappropriately regarded as a benign infection. Research on P. 
falciparum was the priority because of its high mortality and, in part, because it has been adapted 
to laboratory cultivation. In contrast, P. vivax cannot be maintained in in vitro cultures, hindering 
fundamental research required to adequately understand its biology, and advance the 
development of vaccines and treatments. 
Research on vivax malaria needs to be substantially expanded over the next decade to 
address the priorities identified by researchers, national malaria control programs, and other 
stakeholders. This article aims to summarize the main knowledge gaps that are critical to P. 
vivax control and elimination. In particular, it focuses on the need to develop tools and 
intervention strategies to achieve more effective prevention, diagnosis, treatment, and 
surveillance of P. vivax. 
BIOLOGY, CULTURE, AND DRUG SCREENING 
Develop methods for continuous cultivation of P. vivax in vitro. 
There is a need to collect, update, share new evidence, and to coordinate research efforts to 
develop suitable in vitro continuous culture protocols for the P. vivax liver stages and for the 
continuous propagation of its blood stages. 
Blood-stage culture of P. vivax. 
In vitro culture of P. falciparum was first developed in 1976,
10
 but there are no similar 
methods for continuous culture of P. vivax–infected red blood cells (RBCs).11 To date, only 
short-term cultures of P. vivax isolates have been achieved.
12
 Cryopreservation for offsite 
processing and further studies of culture-adapted P. vivax has been shown to be possible,
13
 but 
still requires standardization and a wider replication. Success in short-term cultivation of P. vivax 
blood stages have already provided key insights into the drug susceptibility and the molecular 
and cellular biology of this parasite.
11–15
 Long-term in vitro culture of P. vivax would allow far 
broader access to laboratory isolates and deeper understanding of the biology of P. vivax, and 
facilitate the development of functional assays. This step is critical in the development of drugs, 
vaccines, new diagnostic tests, and to obtain gametocytes needed to infect mosquitoes to provide 
sporozoites for investigation of the liver stages. 
Liver-stage culture of P. vivax. 
The main challenge in P. vivax control and elimination is the inability to kill the hypnozoite 
without the significant safety issues of administering 8-aminoquinolines to patients with G6PD 
deficiency. New and safer hypnozoitocidal therapies would represent an enormous stride forward 
in eliminating P. vivax. 
Screening of compounds for activity against hypnozoites currently relies on an animal model 
(using the closely related parasite, Plasmodium cynomolgi in rhesus monkeys). Recent 
development has allowed drug compounds to be screened using a P. cynomolgi liver-stage 
model.
16
 This in vitro assay represents a major advance and significantly increases the number of 
molecules that can be tested while substantially reducing costs. In contrast to other such systems, 
this one is capable of assessing hypnozoitocidal activity rather than just causal prophylactic 
activity. In other words, it permits assessing impacts upon hypnozoites by allowing their 
awakening and maturation to active liver schizonts. 
Efforts to refine these systems are underway in several laboratories and ongoing challenges 
include finding stable and receptive hepatocyte cell lines or a reliable source of primary 
hepatocytes, securing a supply of viable sporozoites (from patients, monkeys, or eventual blood-
stage in vitro culture). 
A recently developed human liver-chimeric mouse model shows promise both for screening 
drug candidates and for elucidating hypnozoite biology, but is still relatively low throughput due 
to expense.
17
 
Investigate key steps in hypnozoite formation, metabolism, and reactivation. 
There is no detailed knowledge of the biology of P. vivax hypnozoites. It is unknown what 
determines sporozoite development and differentiation into liver schizonts versus hypnozoites. 
Several decades ago, Shute and others conducted human challenge trials, the results of which 
seemed to suggest that the process leading to hypnozoite differentiation was genetically 
predetermined.
18
 There is also no understanding of whether hypnozoites are metabolically active 
during their dormancy period, or what triggers their reactivation. Understanding these processes 
will be essential for developing both novel diagnostic markers that might identify hypnozoite 
carriers and novel therapies that would impede hypnozoite formation, eliminate the hypnozoite, 
or trigger the reactivation of hypnozoites to make parasite stages that are susceptible to available 
antimalarial drugs. The recent development of a humanized mouse system with reactivating 
hypnozoites
17
 as well as the development of P. vivax systems biology resources should aid this 
endeavor. 
Find important processes in the invasion of reticulocytes and study infected RBC 
membrane structures. 
Plasmodium vivax RBC invasion is a complex process which differs from that of P. 
falciparum. After invasion, P. vivax actively remodels the RBC membrane creating complex 
structures such as caviola–vesicle complexes, which are thought to result in the Schuffner’s dots 
visible on Giemsa-stained blood films. The changes result in an extreme flexibility of the 
membranes of P. vivax–infected RBCs. A better understanding of how P. vivax invades 
reticulocytes, why it preferentially does so (as opposed to infecting other more mature RBCs), 
and how it remodels the RBC membrane after invasion would facilitate the identification of 
novel vaccine candidate antigens and potential drug targets. 
Reexamine cytoadherent properties of P. vivax and their potential role in avoiding spleen 
clearance. 
Much of the morbidity and mortality associated with P. falciparum is due to its ability to 
cytoadhere to endothelial cells, resulting in parasite sequestration in small blood vessels and 
resultant organ failure. Although P. vivax is known to adhere to vascular endothelium, its 
capacity to do so is relatively limited compared with P. falciparum,
19
 and little is known 
regarding the mechanisms of P. vivax cythoadherence to those and other human tissues. There is 
a need to better understand the role, magnitude, and reversibility of such processes in P. vivax, 
both in (severe) pathology and in the maintenance of chronic P. vivax infections. A measure of 
the parasite sequestered biomass (and location) in vivo is needed, and in particular, P. vivax 
sequestration in organs like bone marrow and the spleen. It has been hypothesized that the bulk 
of P. vivax biomass may occur in those tissues compared with peripheral blood,
20
 and some 
evidence supports that view.
21
 
EPIDEMIOLOGY 
Develop strategies to distinguish relapses from recrudescence and reinfection. 
Current understanding of relapse patterns of different vivax strains is mostly derived from 
either experimental challenge or clinical studies in soldiers at war in the Pacific carried out over 
50 years ago, and these are not likely to be repeated on any similar scale. To better understand 
the epidemiology of P. vivax relapses,
22
 tools or assay strategies that are able to distinguish 
between recrudescence, new infection, and relapse are needed.
23
 Development of such tools 
would facilitate assessment of drug efficacy against P. vivax, help identify short- and long-
latency phenotypes within endemic areas, and pave the way towards identifying hypnozoite 
diagnostic markers and triggers for relapse. They would also lead to a better understanding of the 
total disease burden due to relapse, which is likely to have been greatly underestimated. Current 
strategies for genotyping recurrent vivax infections rely mostly on microsatellite markers, and 
have revealed that relapses are often multiclonal and usually heterologous (displaying a different 
genotype compared with the preceding blood-stage infection in the same individual).
24,25
 The 
application of next-generation sequencing technologies has the potential to shed more light on 
the genetic signatures of relapse (e.g., that they are meiotic siblings)
26,27
 that maybe be exploited 
to develop better genotyping methods. 
In parallel, innovative epidemiological studies in well-characterized clinical cohorts suffering 
relapse are extremely useful to clarify the attributable fraction of relapse to new infections, 
identify late recurrences, determine the efficacy of antirelapse intervention, and study relapse 
biology in vivo.
28
 For example, further studies in persons returning to nonendemic areas
29
 
followed up for at least 6 months to 1 year, have been conducted in the context of clinical trials 
of antirelapse therapies. 
Explore the epidemiology of P. vivax transmission by characterizing the infective reservoir 
and the contribution of relapses to sustaining transmission. 
Current knowledge of the epidemiology and dynamics of P. vivax transmission is limited. 
Plasmodium vivax gametocytes develop earlier in the blood-stage infection cycle and more 
rapidly than those of P. falciparum and often appear before clinical symptoms.
30
 Plasmodium 
vivax gametocytemia tracks asexual parasitemia closely. A small number of studies have shown 
that P. vivax gametocytes are transmitted more efficiently to some anopheline mosquito vectors 
than in P. falciparum, and P. vivax gametocytes are transmissible at lower parasite densities.
7
 
However, knowledge on the relationship between P. vivax gametocyte density and infectivity to 
the mosquito is weak. For example, in low-transmission settings, the majority of P. vivax 
infections are asymptomatic and of low parasite density, and most of these infections carry 
gametocytes, but the contribution of this feature to transmission in different epidemiological 
settings is not well understood. There is a need for further in-depth epidemiological, 
entomological, and infectivity studies in different epidemiological settings to better understand 
and target P. vivax transmission. 
To date, few studies have successfully measured the relative contributions of new mosquito 
inoculations of P. vivax sporozoites versus the activation of dormant hypnozoites to the overall 
force of blood-stage infection.
31
 Ongoing studies in Papua New Guinea, where P. vivax relapses 
earlier than subtropical strains, indicate that relapses are responsible for up to 80% of P. vivax 
blood infections and contributed substantially to both clinical episodes and transmission.
28,32
 
Other studies in Thailand and Papua, Indonesia, indicate high prevalence of patent 
gametocytemia in relapsing infections, highlighting the importance of radical cure for reducing 
the transmission potential of P. vivax.
33
 
A better understanding of the contribution of relapses to the infectious reservoir and their 
importance for sustaining transmission in areas with low transmission and/or long-latency 
phenotypes is important for the development of rational, evidence-based strategies for 
combatting and eliminating endemic vivax malaria. 
Investigate the pathophysiology of severe P. vivax malaria and its associated global disease 
burden. 
Although long considered benign by malariologists and clinicians, the advent of polymerase 
chain reaction (PCR) diagnostics in the clinic beginning in the 1990s saw the emergence of a 
body of evidence associating acute P. vivax with severe and fatal outcomes. That evidence has 
been built into a compelling case for discarding the ―benign‖ label as misleading and dangerous, 
and instead viewing and managing vivax malaria as a serious and life-threatening infection.
2
 
It has been suggested that in settings where malaria is endemic, inadequate therapy and 
repeated relapses are important contributing factors for severe morbidity and mortality with 
vivax malaria, particularly that of severe anemia.
21,34
 Specific vulnerable groups, such as 
pregnant women, have also been suggested to be at increased risk of developing severe disease.
35
 
Their fetuses are at a 4-fold increase in risk of spontaneous abortion after even a single clinical 
attack of P. vivax in the first trimester.
36
 Many uncertainties still shadow our understanding of 
the mechanisms through which P. vivax may trigger events leading to severe and threatening 
illness in an as yet unknown proportion of cases. 
Further studies assessing the pathophysiology
21,37
 in vivo or using postmortem samples
38
 will 
be required to better understand the mechanisms related to severe disease, and the role of 
cytoadhesion and other means of sequestration
39
 and/or inflammation in pathogenesis. The role 
of concomitant infections and comorbidities in the development of severe manifestations still 
needs to be elucidated.
40
 
The WHO’s currently proposed working definition for severe P. vivax malaria, derived from 
an expert review meeting on severe malaria essentially states that ―the criteria for severe vivax 
malaria are the same as for adults and children with severe falciparum malaria but with no 
parasitaemia density thresholds (and without the criterion of hyperparasitaemia).
2
 A more 
specific expert consensus on standards for case reporting, retrospective and prospective hospital-
based studies, and, importantly, village-based assessments of morbidity and mortality by species 
should be undertaken.
2,20
 Efforts should be made to carry out these investigations across 
representative zones of endemicity.
35
 There is also a need to conduct studies to validate optimal 
approaches for the management of patients with severe P. vivax disease.
40
 
Estimate the burden of P. vivax malaria in sub-Saharan Africa. 
Duffy-negative phenotype in humans was believed to confer complete protection against P. 
vivax blood-stage parasites, because of the generalized acceptance that parasites could only 
invade the RBC using the Duffy receptor.
41,42
 Nevertheless, there is growing evidence supporting 
the presence of P. vivax infections among Duffy-negative populations in defined areas of sub-
Saharan Africa in addition to Madagascar and Mauritania.
43,44
 This suggests alternative 
reticulocyte invasion pathways used by the species
45
 that should be investigated and identified. 
In addition, P. vivax associated with severe complications has been reported from African 
countries.
46–48
 However, the degree to which different populations living in sub-Saharan Africa 
are affected by P. vivax malaria remains unknown. The consistent finding of confirmed P. vivax 
in Europeans traveling to west and central sub-Saharan Africa
49
 suggests that endemic 
transmission occurs despite the overwhelming dominance of Duffy negativity among residents. It 
may be that endemic P. vivax indeed occurs but is not prevalent at levels where it may be 
detected by routine means. 
There is a need to estimate whether there is a significant P. vivax burden in sub-Saharan 
African populations to determine whether appropriate screening, management, and surveillance 
of P. vivax cases should be considered as part of program activities, and if so, which diagnostic 
methods to use for this screening. 
Map prevalence and severity of G6PD deficiency and CYP2D6 poor metabolizers in 
endemic areas. 
The presence of G6PD deficiency is a major operational obstacle to the implementation of 
antihypnozoite therapy with 8-aminoquinolines. Countries have an increasing understanding of 
the prevalence and severity of the G6PD genotypes present in their populations, but it is still 
inadequate to assess risk and guide clinical and public health decision-making. Even less is 
known about the prevalence of the trait among P. vivax patients. As G6PD deficiency is known 
to be associated with protection against malaria, including P. vivax,
50
 its prevalence in P. vivax 
patients is expected to be lower than in the general population, thus altering the risk-benefit ratio 
of 8-aminoquinoline therapy.
51
 A better understanding of the geographical distribution of severe 
G6PD-deficiency alleles in general and in P. vivax patients in particular would assist 
development of evidence-based guidelines for 8-aminoquinoline therapy. 
Information on G6PD genotypes, biochemical phenotypes, and degree of hemolysis caused 
by PQ in specific endemic areas will assist in the development of screening and treatment 
strategies for PQ that mitigate the harm caused by the drug or that of the parasite by withholding 
it, that is, repeated clinical attacks originating as untreated hypnozoites. 
PQ is a prodrug shown to be metabolized by the CYP2D6 isozyme of cytochrome P-450. 
People with specific CYP2D6 polymorphic alleles fail to metabolize PQ and may thus fail 
treatment,
52
 leading to false assumptions of PQ tolerance in the parasite. It is currently not clear 
to what degree CYP2D6 activity impairment may cause therapeutic failure against hypnozoites 
(or gametocytes of P. falciparum as well) or how common such CYP2D6 alleles may be among 
different P. vivax–endemic areas. Better information on the CYP2D6–PQ interaction in different 
P. vivax–endemic regions will help understand the rates of PQ failures and help improve the 
overall effectiveness of antirelapse therapy in realizing crucial clinical and public health 
therapeutic objectives. 
PREVENTION AND TRANSMISSION INTERRUPTION 
Develop integrated vector control interventions that target outdoor and early biting 
transmission and protect vulnerable populations. 
A literature review identified 71 species/species complexes of anopheline mosquitoes with 
the potential ability to transmit P. vivax.
7
 Many of these species are more exophilic and less 
anthropophilic than highly efficient vectors such as the African vector species, Anopheles and 
ITN (including LLIN). 
Decades of vector control based on indoor insecticidal strategies targeting endophilic 
mosquitoes have led to shifts to greater outdoor and earlier biting behavior,† or shifts in 
dominant vector species.‡ In addition, P. vivax seems to develop more rapidly in the mosquito 
than P. falciparum, thus limiting the efficacy of methods that aim at shortening the mosquito 
lifespan, such as ITNs and IRS. As a consequence, methods of control that are broadly more 
effective in reducing P. falciparum transmission, such as ITNs, are less successful in controlling 
P. vivax.
54
 
New tools should be adapted to human and vector behaviors. In particular, the development 
of integrated vector control interventions targeting outdoor and early biting transmission before 
sleeping time is of high priority. Existing tools need to be optimized (e.g., formulations of long-
lasting nonpyrethroid IRS), more appropriate delivery mechanisms have to be devised and tested, 
and new or innovative control methodologies involving biological and genetic approaches have 
to be evaluated. These include, among others, safe, novel, longer lasting, and reformulated 
synthetic insecticides; insecticide-treated durable wall lining, plastic sheeting, and other 
materials; topical and spatial repellents; insect growth regulators such as pyriproxfen, attractive 
toxic sugar baits, entomopathogenic fungi and other pathogens, and endosymbionts such as 
Wolbachia.
55
 
New tools are needed to prevent P. vivax transmission, especially in vulnerable and special 
at-risk groups such as pregnant and lactating women, infants, or forest workers. In fact, vector 
control tools may be the only available tools for harm reduction among pregnant women and 
infants since PQ is contraindicated in these two groups. 
Strengthen entomological research by developing more sensitive vector surveillance tools 
and standardizing protocols for evaluating vector control interventions. 
More sensitive vector surveillance tools—including the use of molecular techniques—are 
needed to identify which vectors are truly the primary vector species of P. vivax so that 
appropriate and targeted control measures are taken. Well-designed large-scale studies are 
needed to evaluate the impact of vector control interventions, alone and in combination, in areas 
where P. vivax is dominant. Standardized and universally acceptable protocols that specify the 
duration of study follow-up, integration of epidemiological and entomological analysis, quality 
control, and assay systems to determine vector behavior exposed to sublethal insecticide 
concentrations are needed. 
Develop a vaccine for P. vivax. 
Plasmodium vivax vaccine development has been hampered by inadequate funding, poor 
laboratory systems for evaluating potential vaccine targets, few vaccine candidates, and very few 
clinical trials. Each of these obstacles reflects the chronic neglect of P. vivax as a research 
priority since 1960. In response, the November 2013 update to the malaria vaccine technology 
roadmap has for the first time included a call for new tools to control and eliminate P. vivax. The 
updated malaria vaccine technology roadmap§ strategy is to develop vaccines to prevent both 
clinical disease and its transmission. 
Disease-preventing vaccines offer the theoretical advantage that vaccine-induced protective 
immunity might be boosted by natural exposure to P. vivax and could therefore extend the 
duration of vaccine protection. On the other hand, such vaccines may exacerbate the serious 
problem of asymptomatic carriers of infection that now seriously impedes elimination in the low-
transmission settings typical of P. vivax endemicity. However, a transmission-blocking vaccine, 
if widely applied in conjunction with other control measures, could potentially more readily 
reduce transmission intensity and more substantially contribute to elimination success. In other 
words, such a product would prevent both primary blood-stage infections and the establishment 
of relapse-causing hypnozoites (in other people). 
One approach for P. vivax disease prevention is to interrupt merozoite invasion of RBCs via 
the critically important ligand–receptor interaction between the P. vivax Duffy-binding protein 
and the human RBC Duffy antigen. At the time of writing, one of the P. vivax vaccine trials in 
the clinical phase of development is based on this approach. However, the description of cases of 
P. vivax malaria among Duffy antigen–negative individuals indicated that additional parasite 
ligands (e.g., from the P. vivax reticulocyte-binding protein family) might need to be 
concurrently targeted to achieve an effective antibloodstage vaccine. 
In addition, there are currently two ongoing clinical trials based on the P. vivax 
circumsporozoite (CS) protein. Since the CS protein is a malaria antigen involved in sporozoite 
invasion of hepatocytes and also present on hypnozoites, it is an attractive target against both the 
sporozoite and intrahepatic parasites.
56
 
Vaccine development for preerythrocytic stages of P. vivax has been hindered by difficulties 
conducting sporozoite challenge trials for P. vivax. These difficulties include the need to obtain 
fresh wild-type isolates for each challenge, the possibility of P. vivax relapses and the 
nonavailability of radical cure with complete efficacy to prevent such relapses. Only a few 
challenge trials have been conducted with limited success. 
A Phase 1 safety and immunogenicity trial of a transmission-blocking vaccine based on the 
sexual stage Pvs25 antigen suffered from undesirable reactogenic side effects. A potentially 
transformative effort for further development is underway to develop an in vitro assay of serum 
antibody–based transmission blocking activity by showing that mosquitoes fed on vaccinated 
individuals do not support the development of P. vivax oocysts and sporozoites. 
An as yet unfunded and unexplored avenue of vaccination offers potential for success—
vaccination by laboratory/factory-reared sporozoites of P. falciparum cross-protecting against 
infection of liver by sporozoites of P. vivax. The ―live sporozoite vaccine‖ technology has shown 
some efficacy with P. falciparum,
57,58
 and some experiments and data suggest cross-species 
protection may occur.
59,60
 
Further development of P. vivax vaccines remains a priority as articulated in the updated 
malaria vaccine technology roadmap. Any vaccine will also have to address the high genetic 
diversity found in P. vivax, which is greater than that found in P. falciparum
61
 and maintained 
even in low-transmission settings. It may be that this area will only move forward if significant 
new research and development resources are obtained. Without this, the area is likely to remain 
neglected. 
CASE MANAGEMENT 
Improve the evidence base for G6PD deficiency testing and management and develop field-
ready point-of-care tests for detecting G6PD deficiency. 
Deficiency of G6PD is a genetic trait widely distributed in populations across malaria-
endemic regions.
62
 Treatment with 8-aminoquinolines such as PQ can trigger threatening acute 
hemolytic anemia in patients with G6PD deficiency. Consequently, treatment of P. vivax 
infection with 8-aminoquinolines should be undertaken with knowledge of the individual’s 
G6PD activity status. The use of PQ in pregnant women is contraindicated, not because of the 
dangers it could cause on G6PD-deficient pregnant women, but because of the uncertainty 
regarding the G6PD status of the fetus. 
At present, the use of a quantitative screening tool that informs the relative degree of enzyme 
activity is the most direct, accessible, and reliable approach, and remains the gold standard for 
G6PD-deficiency assessment.
63
 Qualitative tests are also available but only inform whether the 
person has a certain high level of G6PD in his or her cells. These tests are used as rapid 
screening tests but usually require a confirmation testing using a quantitative test, with which the 
actual amount of enzyme activity is measured. Genotyping studies and enzyme activity assays 
can also be used; however, these methodologies have significant limitations such as false 
negatives, high costs, or specialized equipment requirements.
63
 In general, however, these 
methods require fully equipped laboratories and highly trained technical staff and, as such, offer 
little utility for the vast majority of patients suffering malaria in impoverished and often isolated 
rural tropical settings. 
Data on the performance of G6PD-deficiency-testing products is limited. A systematic 
evaluation of G6PD-deficiency-testing products that are currently available should be carried out 
in endemic settings to provide a comparative measure of their performance in a standardized way 
and to distinguish between adequate and poorly performing tests. Moreover, there is a need to 
evaluate the effects of acute malaria on G6PD tests, since G6PD-deficient patients who have 
recently suffered hemolysis may have a normal G6PD test. 
To improve G6PD-deficiency testing, further research studies have to be conducted to 
determine the relationship between G6PD genotype, the level of enzyme activity, and the risk of 
hemolysis following different dosing regimens of 8-aminoquinolone antimalarials. Current 
qualitative tests for G6PD deficiency have limitations in guiding treatment with PQ in most 
heterozygous females.
64
 The phenomenon of lyonization of this X-linked trait explains this 
problem, that is, a variable proportion of RBCs will express mutant G6PD and fully impaired 
enzyme activity. The clinical risk this poses to females remains unknown. 
Ultimately, there is a need for developing a rapid, inexpensive, and accurate point-of-care 
test for detecting G6PD deficiency that can be used before PQ treatment in endemic countries.
1,63
 
This type of test should clearly distinguish the enzyme activity above which it is safe to give 
therapeutic doses of PQ.
62,63
 A point-of- care G6PD quantitative test that functions as a combo 
test and also measures hemoglobin level simultaneously should become available in 2016, 
including a built-in thermometer to monitor optimum temperature for the assay (PATH-GSK; 
http://sites.path.org/dx/malaria/g6pd/). Such a test will require evaluation under field conditions 
in endemic areas. 
Improve methods for defining antimalarial efficacy. 
In areas with chloroquine-resistant P. vivax, artemisinin-based combination therapies (ACTs) 
are recommended by the WHO for the treatment of the acute attack.
9
 This offers a unified ACT-
based strategy for treating both P. falciparum and P. vivax infections in regions where both 
species are endemic. Unfortunately, current methods for defining antimalarial efficacy in P. 
vivax are more challenging than in P. falciparum, due to the confounding effects of relapse 
episodes (see above). Also, while many molecular markers for drug resistance have been 
described for P. falciparum, well-defined genetic mutations that confer chloroquine resistance in 
P. vivax remain elusive but represent an area of intense study.
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 Better methods for defining 
antimalarial efficacy are required to be able to define when chloroquine or ACT efficacy is 
compromised. Similar methods for measuring antirelapse efficacy of 8-aminoquinolines are also 
lacking but critical for evaluating new hypnozoitocidal therapies. 
Define the role of ACTs in P. vivax treatment. 
ACTs have been adopted as the first-line therapy against P. vivax in a handful of countries: 
Cambodia, Indonesia, Vanuatu, Solomon Islands, and Papua New Guinea.
66
 
However, more information is required regarding the efficacy and safety of the different 
ACTs combined with PQ, as well as the activity of PQ against relapse when combined with 
ACTs instead of chloroquine.
30,66
 In addition, cost-effectiveness analyses are required to 
compare ACTs and chloroquine for vivax malaria and to assess the role of these drugs in vivax 
malaria control and elimination efforts at different transmission intensities.
66
 
Learn how to administer PQ therapy safely and effectively. 
The primary aim of the radical cure of P. vivax is to ensure the elimination of both the acute 
blood-stage infection and the hepatic hypnozoites. This requires administration of two classes of 
therapies—blood schizontocidal and hypnozoitocidal. Evidence on the efficacy of several widely 
used PQ regimens is lacking, including those employing ACT as partner drug in radical cure. 
Antirelapse clinical trials are needed to optimize current policies and practices.
1
 For instance, 
assessment of short-course, high-dose PQ regimens in studies with long follow-up period is 
crucial as potential new strategies to improve patient’s adherence.1 Further studies are needed to 
define the risk benefit of PQ, since both recurrent episodes of malaria and hemolytic reactions 
from the drug can result in severe anemia. Evidence is also needed regarding the total dose 
(which appears to be the key determinant of efficacy) of PQ required to prevent relapses, and this 
will need to be assessed in different geographical locations.
1
 
In addition, data regarding the safety and efficacy of modified PQ regimens (e.g., weekly 
doses) for individuals with G6PD deficiency are also required. 
Develop guidelines for PQ use in children. 
Although PQ pharmacokinetics have been partially characterized in studies of healthy 
subjects and adult males with malaria, there are few data available in young children, one of the 
most vulnerable populations at risk of recurrent episodes of vivax malaria.
67
 However, a recent 
review of the literature reveals 11 clinical studies of PQ therapy that recruited patients under 4 
years of age. Although age-stratified tolerability was not reported, the overall safety profile of 
PQ in G6PD normal individuals was excellent and no worse than for other antimalarial drugs.
67
 
Current WHO recommendations, issued in 2015, have recognized this and now allow the use of 
PQ in children older than 6 months.
68
 
Still, more evidence is needed on the efficacy, safety and pharmacokinetics of PQ in young 
children. The lack of provision of radical cure for infants represents not only a failure to reduce 
morbidity in this most vulnerable population but also a lost opportunity to have an impact on P. 
vivax transmission.
1
 
Develop alternatives to 8-aminoquinolines. 
Tafenoquine, an antimalarial drug invented by the U.S. Army over 30 years ago, is currently 
the only alternative to PQ being developed with proven efficacy against hypnozoites.
69
 Once 
licensed, this drug will offer the enormous advantage of a single-dose treatment against relapse. 
However, as an 8-aminoquinoline, its use remains constrained to the knowledge of the G6PD 
status of the individual to whom it needs to be administered, similarly to PQ. Innovative G6PD 
diagnostic technologies may greatly mitigate this problem and permit the full clinical and public 
health benefits this new therapy promises. Development of effective hypnozoitocidal drugs for 
preventing P. vivax relapses and offering safety in G6PD-deficient patients is a key research 
priority when considering malaria elimination and eventual eradication. The use of drugs with 
hypnozoitocidal activity will be crucial not only to prevent relapses in infected patients but also 
to reduce P. vivax transmission potential. 
Develop strategies to prevent relapse in patients unable to receive PQ. 
As explained, pregnant or lactating women, their infants, and perhaps those diagnosed with 
G6PD deficiency cannot receive PQ therapy. CYP2D6-impaired patients may add further to this 
classification of patients. They require alternatives to PQ as a means of preventing relapse. These 
may include chemoprophylactic or chemopreventive strategies, for example, intermittent 
preventive treatment of pregnant women and infants in sub-Saharan Africa. Most of those 
optimized and validated regimens, however, use sulfadoxine–pyrimethamine, and these are 
ineffective against P. vivax. The research community must conceive, evaluate, optimize, and 
validate strategies for preventing relapse in patients unable to receive PQ. 
OPERATIONAL AND HEALTH SYSTEMS RESEARCH 
Improve diagnostics for surveillance and elimination. 
A large proportion of P. vivax infections are asymptomatic with low and submicroscopic 
parasite densities.
70
 Studies should assess the public health significance of subpatent P. vivax 
infections,
1
 both in terms of chronic morbidity (e.g., anemia) and their contribution to 
transmission (see above). 
In the context of malaria elimination, new, affordable diagnostics that can rapidly and 
accurately diagnose low-density P. vivax infections are required to detect asymptomatic parasite 
reservoirs resident in blood. Having a field-ready (i.e., findings rendered within a time frame 
permitting administration of therapy to those infected) diagnostic tool to detect low levels of 
parasitemia will facilitate active case detection and help monitor progress towards malaria 
elimination.
71
 PCR-based techniques have good analytical sensitivity but are difficult to 
implement under field conditions, whereas loop-mediated isothermal amplification (LAMP) 
technology represents a more feasible method in resource-limited field settings that still 
maintains good sensitivity to detect Plasmodium parasites.
72
 Further research is needed to assess 
the cost-effectiveness and implementation challenges of LAMP technology for pursuing active 
case detection in malaria-elimination settings. A serological diagnosis of acute, subpatent, or 
latent malaria has not been adequately explored. These technologies have for decades been 
successfully applied to other infections difficult to diagnose by demonstrating the agent or its 
DNA/RNA signature. 
Develop strategies to target the hypnozoite reservoir. 
It must be recognized that diagnostic tests based on the detection of blood-stage infections do 
not identify a significant proportion of the reservoir of disease: carriers of the hypnozoite who 
show no outward signs of disease and who often do not have blood-stage parasitemia. Diagnostic 
tests that can either directly identify hypnozoite carriers or alternatively identify people at high 
risk of recurrent parasitemia (e.g., by identifying people with recent exposure to P. vivax) would 
allow better identification and targeting of the infectious reservoir which is key to transmission 
reduction. 
Since there are currently no diagnostic methods that allow the identification of individuals 
that harbor hypnozoites, mass screening and treatment approaches are likely to be ineffective 
against P. vivax since the hypnozoite reservoir is undetected at the screening and therefore 
untreated. Mass drug administration (MDA) with an 8-aminoquinoline–containing regimen may 
thus be a more appropriate approach. However, in low-transmission and preelimination settings, 
most people may not carry hypnozoites. Given the risk of hemolysis and the difficulty of 
implementing community-wide G6PD testing, evidence to support alternative MDA strategies is 
needed, for example, to target high-risk groups (such as those working in endemic areas, 
travelers, or those with confirmed recent exposure). 
Evaluate the efficacy of current tools against P. vivax. 
Improving the understanding of the efficacy, effectiveness, cost-effectiveness, and 
appropriate mix of insecticide-treated nets, preventive treatment, and/or IRS in vivax malaria 
control is required. These interventions should be examined against endemic vivax malaria in 
context-specific settings representative of the Americas, south Asia, southeast Asia and the 
Pacific. 
The relatively low transmission and thus large sample sizes required for formal clinical trials 
makes direct evaluation difficult and costly. Alternative approaches that combine in silico 
prediction of efficacy using well-validated P. vivax mathematical transmission models
73
 with 
careful evaluation of programmatic implementation studies, may thus be more cost-effective. 
This will, however, require further development of P. vivax–transmission models, in particular of 
models for low-transmission settings and the role of the hypnozoite reservoir. 
Improve access to antirelapse therapy. 
Given the key role of P. vivax relapses, it is essential to improve access to antirelapse therapy 
for all P. vivax patients. In many areas, this will not only require implementing evidence-based 
PQ regimens but also the development approaches for facility-based G6PD testing and/or 
monitoring for signs of hemolysis. 
A high priority will be to conduct operational research to optimize delivery of antirelapse 
therapy safely and effectively in different settings including strategies to ensure adherence to 
treatment. 
Develop novel approaches to surveillance and optimize strategies for detection of residual 
transmission “hot spots.” 
As transmission ebbs to very low levels and becomes geographically fragmented, the nature 
of surveillance systems needs to change. The focus shifts to the detection of foci of residual 
transmission and different forms of reactive surveillance (triggered by the detection of an index 
case) should be adopted. At the same time, in those settings, the surveillance strategies have to 
be used to direct the response. 
In low-transmission areas or areas targeting elimination, serological surveys of recent 
infection may be better suited to the identification of P. vivax transmission foci than traditional 
mass-blood surveys that only detect current patent infections. A different surveillance approach 
would be to develop genotype maps of P. vivax infection at the district level to better understand 
the local dynamics of P. vivax transmission. A formal evaluation of different surveillance 
approaches and their effectiveness in different epidemiological settings is needed. 
Use modeling to understand current status and future perspectives for vivax malaria. 
Epidemiological modeling can be used to assess and quantitatively analyze the current state 
of the P. vivax situation on a global and/or local scale. This will assist in examining the probable 
impact and improved targeting of interventions previously discussed. This may also assist in 
optimizing the mix of interventions needed for the interruption of transmission in P. vivax–
endemic areas.
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CONCLUSIONS 
Identifying the specific challenges to control and prevention of P. vivax is of paramount 
importance to the global fight against malaria. Without a special focus on vivax malaria,
75
 local 
elimination will remain elusive and the tremendously ambitious goal of malaria eradication will 
be more costly, take longer, and its ultimate success less probable. In this respect, intense 
scientific research is required to adequately address the many knowledge gaps that surround this 
parasite species. 
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† For example, Anopheles gambiae (Bioko Island, Kenya, Tanzania), An. gambiae s.l. (Nigeria) and Anopheles funestus 
(Tanzania, Benin), Anopheles farauti and Anopheles koliensis (Papua New Guinea, Solomon Islands), Anopheles sinensis, 
Anopheles lesteri (syn. Anopheles anthropophagus), and Anopheles minimus s.l. (China), Anopheles dirus, Anopheles maculatus 
s.l., and Anopheles minimus s.l. (Vietnam), An. dirus s.l. and An. minimus s.l. (Thailand, Vietnam), Anopheles darlingi (Brazil, 
French Guiana, Guatemala), Anopheles fluviatilis s.l. (Nepal). 
 
 
 
‡ For example, from Anopheles funestus to Anopheles gambiae s.l. (Tanzania-Kenya border, Niger), from An. gambiae s.l. to 
Anopheles arabiensis (Niger, Kenya, The Gambia, Tanzania) or Anopheles merus (Pemba Island in Tanzania), from Anopheles 
koliensis and Anopheles punctulatus to Anopheles farauti (Solomon Islands), from Anopheles minimus to Anopheles harrisoni 
(Thailand, Vietnam), from Anopheles lesteri to Anopheles sinensis (China), and from Anopheles darlingi to Anopheles aquasalis 
(British Guiana).53 
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